Comparison study between tween 20 and tween 80 as an edge activator for preparation of transdermal ondansteron HCL transfersomal nano particles
Main Article Content
Keywords
.
Abstract
In ordinary clinical practice, poor patient compliance with oral and parenteral drug administration modalities is a prevalent problem. As a result, pharmaceutical research has developed a strong interest in the transdermal route of drug delivery. They are noninvasive, self-administered administration techniques that can improve patient compliance. However, the barrier function of the skin’s top layer presents the biggest challenge for transdermal delivery systems. Ionized chemicals and compounds with molecular weights greater
than 500 Da cannot pass through skin. As a result, this method can only be used to deliver a few medicines. A possible solution to this issue is to include the medications in transfersomes. Transfersomes are vesicles composed of phospholipids and edge activators, used to transport drug from outer skin layer into the systematic circulation through a semipermeable membrane. Tween 20, 80 (Polysorbates) are edge activators employed in medicines for a variety of reasons, including modifying the absorption of active ingredients. Ondansetron is an antiemetic medication that has been given parenterally and orally. Formulating this medication as transdermal transfersomes may provoke a great advantage in medical adherence
References
2. Li J, Wang X, Zhang T, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015; 10: 81–98. https://doi.org/10.1016/j.ajps.2014.09.004
3. Kováčik A, Kopečná M, and Vávrová K. Permeation enhancers in transdermal drug delivery: benefits and limitations. Exp Opin Drug Deliv.
2020 Feb 1; 17(2): 145–155. https://doi.org/10.1080/17425247.2020.1713087
4. Jeong WY, Kwon M, Choi HE, et al. Recent advances in transdermal drug delivery systems: a review. Biomater Res. 2021 Dec; 25(1): 24. https://doi.org/10.1186/s40824-021-00226-6
5. Walve JR, Bakliwal SR, Rane BR, et al. Transfersomes: a surrogated carrier for transdermal drug delivery system. Int J Appl Biol Pharm
Technol. 2011; 2(1): 204–213.
6. Sachan R, Parashar T, Soniya SV, et al. Drug carrier transfersomes: a novel tool for transdermal drug delivery system. Int J Res Dev Pharm Life Sci. 2013; 2: 309–316.
7. Venkatesh D, Kalyani K, Tulasi K, et al. Transfersomes: a novel technique for transdermal drug delivery. J Drug Deliv Ther. 2019; 9(1): 279–
285. https://doi.org/10.22270/jddt.v9i1.2198
8. Modi C, and Bharadia P. Transfersomes: new dominants for transdermal drug delivery. Am J Pharm Tech Res. 2012 Jan 1; 2.
9. Piumitali B, Neeraj U, and Jyotivardhan J. Transfersomes – a nanoscience in transdermal drug delivery and its clinical advancements. Int J Nanosci. 2020 Aug; 19(4): 1950033. https://doi.org/10.1142/S0219581X19500339
10. Patel RP, and Baria AH. Formulation and evaluation considerations of transdermal drug delivery system. Int J Pharm Res. 2011; 3: 1–9.
11. Mathur M. Approaches for improving the pharmacological and pharmacokinetics properties of herbal drugs. Int Res J Pharm Appl Sci. 2013; 3: 40–50
12. Jadupati M, and Kumar NA. Transferosome: an opportunistic carrier for transdermal drug delivery system. Int Res J Pharm. 2012; 3: 35–38.
13. Jiang T, Wang T, Li T, et al. Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma. ACS Nano. 2018; 12: 9693–9701. https://doi.org/10.1021/acsnano.8b03800
14. Garg V, Singh H, Bimbrawh S, et al. Ethosomes and transfersomes: principles, perspectives and practices. Curr Drug Deliv. 2016; 14: 613–633. https://doi.org/10.2174/1567201813666160520114436
15. Midatech’s Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent PostOperative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US: Press Release.
16. PubChem. Ondansetron. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/4595 [cited 2022 May 10].
17. Fleming RA, Olsen DJ, and Savage PD. Am J Health Syst Pharm. 1995; 52(5):14. https://doi.org/10.1093/ajhp/52.5.514
18. Ghanbarzadeh S, and Arami S. Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes. Biomed Res Int. 2013; 2013: 616810. https://doi.org/10.1155/2013/616810
19. Yang H, Wu X, Zhou Z, et al. Enhanced transdermal lymphatic delivery of doxorubicin via hyaluronic acid based transfersomes/microneedle complex for tumor metastasis therapy. Int J Biol Macromol. 2019 Mar; 125: 9–16. https://doi.org/10.1016/j.ijbiomac.2018.11.230
20. Jangdey MS, Gupta A, Saraf S, et al. Development and optimization of apigenin-loaded transfersomal system for skin cancer delivery: in vitro evaluation. Artif Cells Nanomed Biotechnol. 2017; 45(7): 1452–1462. https://doi.org/10.1080/21691401.2016.1247850
21. Nasri S, Ebrahimi-Hosseinzadeh B, Rahaie M, et al. Thymoquinone-loaded ethosome with breast cancer potential: optimization, in vitro and biological assessment. J Nanostruct Chem. 2020; 10(1): 19–31. https://doi.org/10.1007/s40097-019-00325-w
22. Bruschi ML. Strategies to modify the drug release from pharmaceutical systems. Elsevier Science; 2015.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.